The targeted production of the ZyCoV-D vaccine from this facility will be mutually agreed upon by both parties.
ZyCov-D is the first DNA plasmid vaccine in the world for human use developed indigenously by CHL against the Covid-19 virus. It is also the first COVID-19 vaccine for adolescents in the 12-18 age group, besides the adult population and is a needle-free vaccine administered using
The PharmaJet a needle free applicator, which ensures painless intradermal vaccine delivery.
CHL will transfer the ZyCoV-D technology to SBPL. Under the agreement, SBPL will be responsible for manufacture of the Drug substance of the vaccine, while CHL is responsible for filling/packaging/distribution/marketing of the vaccine in its marketing territories.
The biologics business has been identified as a strategic growth engine by SML and it has made significant investments in setting up a high end, flexible biologics facility in SBPL.
This facility at Dharwad would cater to the requirements of the fast-growing biologics field, that include the DNA vaccine, adenoviral, subunit vaccines, monoclonal antibodies & fusion proteins.
At around 2:39 PM, Shilpa Medicare was trading at Rs571 per piece down by 0.19% while Cadila Healthcare was also tumbling by 0.33% at 565.05 per piece.